Options of adjuvant treatment in such synchronous tumors include radioactive iodine therapy, endocrine therapy, and targeted drug therapy like tyrosine kinase inhibitors and selective RET inhibitors for RET mutant MTC, based on the stage of the disease. This evidence concerns the gene RET and medullary thyroid gland carcinoma.